Board Change


C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

20 June 2023 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that Eva-Lotta Allan will step down as Chair after five years of service with immediate effect. Clive Dix will simultaneously become interim Executive Chair and a search will commence to find a new Chief Executive Officer.  Clive Dix, who has held a variety of leadership roles at C4XD over the past nine years, will be interim Executive Chair until a new CEO is appointed in order to ensure a smooth transition, after which point it is expected that he will assume a Non-Executive Board role.

Eva-Lotta became Chair in July 2018 and steps down now to focus on her portfolio of other Board director roles.  The search will now be initiated to recruit a new CEO of C4XD, ideally with strong leadership skills, an international network and IR experience in global public markets, and a track record of building a company with products that have entered clinical development.

Clive Dix, CEO of C4XD, said: “I would like to thank Eva-Lotta, both personally and on behalf of the Board for her guidance and support over the past five years as, together, we have built C4XD into a strong company with an established reputation for drug discovery expertise.  The business is one I feel extremely confident and passionate about and I look forward to working with the Board to find a suitable CEO successor to continue to drive our new strategy forward with the focus in immuno-inflammatory diseases.” 

Eva-Lotta Allan, Chair of C4XD, commented: “Over the past five years we have built a commercially attractive pipeline and executed several value-creating deals for C4XD programmes with leading pharma companies and, after five years, I now feel it is the right time to hand the reigns to Clive as interim Executive Chair.  A smooth succession plan will allow us to bring in a new CEO with the right experience to take the Company to its next stage, thereby ensuring that C4XD continues to deliver on its vision, strategy and, most importantly new therapies to improve the lives of patients with immuno-inflammatory diseases. I have enjoyed working with the CX4D team and the Board and wish everyone at C4XD well.”

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (“C4XD”) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced candidate molecule design and patient stratification capabilities, generating small molecule drug candidates across multiple disease areas focused on immuno-inflammation.  Our commercially attractive portfolio ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have three commercially partnered programmes with one candidate in clinical development.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.